RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Merck China plans to add a life sciences section to its upstream technology research & development center in Zhangjiang Hi-Tech Park in Shanghai.
Merck China will expand the center next year to 1,000 square meters with more than 20 scientists and engineers, a representative of the US pharma giant’s China unit told Yicai Global. Merck will establish a complete media service system combining the center with its Nantong Life Science Center to be built next year. The enterprise aims to reduce customer response time by localizing R&D centers and accelerating sample testing for production.
The center will be Merck’s largest such facility in the region, according to Benoit Opsomer, vice president of Merck’s life sciences.
The company has invested EUR80 million (USD90.5 million) over two years in Nantong Life Science Center as well as in its first Asian end-to-end bioprocess development center in Shanghai, and a one-time technology production base in Wuxi, Jiangsu.
This 350-year-old firm has been increasing investments in life sciences in recent years, hoping to transform into an innovative technology company. China is regarded as a top priority due to its position as one of the top five markets in the globally. Merck has invested EUR250 million in China, Opsomer said.
Merck is the first multinational company to introduce medium development and non-good manufacturing practice pilot production capabilities in China.
Source: yicaiglobal.com
